CRIS Current Research Information System

MANCINI, MANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.880
AS - Asia 3.264
EU - Europa 2.733
AF - Africa 243
SA - Sud America 166
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.294
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.841
SG - Singapore 966
VN - Vietnam 916
CN - Cina 784
GB - Regno Unito 649
IT - Italia 422
DE - Germania 382
SE - Svezia 336
HK - Hong Kong 245
NL - Olanda 165
RU - Federazione Russa 153
IN - India 144
IE - Irlanda 133
UA - Ucraina 130
BR - Brasile 118
FR - Francia 109
TG - Togo 88
ZA - Sudafrica 55
EE - Estonia 53
CI - Costa d'Avorio 52
FI - Finlandia 48
KR - Corea 42
JP - Giappone 41
JO - Giordania 33
BG - Bulgaria 30
CH - Svizzera 30
CA - Canada 25
NG - Nigeria 25
IR - Iran 22
AR - Argentina 19
BE - Belgio 19
ID - Indonesia 18
SC - Seychelles 14
EC - Ecuador 13
PL - Polonia 12
ES - Italia 10
GR - Grecia 10
MX - Messico 10
TR - Turchia 10
BD - Bangladesh 9
AT - Austria 8
CZ - Repubblica Ceca 8
IQ - Iraq 8
HR - Croazia 5
LB - Libano 5
RO - Romania 5
AU - Australia 4
CL - Cile 4
LT - Lituania 4
UZ - Uzbekistan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
MA - Marocco 3
NO - Norvegia 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
DK - Danimarca 2
KH - Cambogia 2
PE - Perù 2
PY - Paraguay 2
AL - Albania 1
AZ - Azerbaigian 1
EG - Egitto 1
GE - Georgia 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LY - Libia 1
MD - Moldavia 1
MM - Myanmar 1
MR - Mauritania 1
MU - Mauritius 1
MY - Malesia 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
SV - El Salvador 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZM - Zambia 1
Totale 10.294
Salva come PNG Salva come JPEG
Città #
Singapore 674
Southend 576
Chandler 469
Ashburn 441
Fairfield 349
Hong Kong 244
Ho Chi Minh City 210
Wilmington 193
Seattle 191
Houston 170
Woodbridge 170
Dong Ket 160
Hanoi 153
Beijing 143
Princeton 138
Dublin 133
Cambridge 131
Ann Arbor 122
Hefei 100
Lomé 88
Santa Clara 88
Bologna 86
Boardman 84
Jacksonville 79
Nanjing 60
Westminster 58
Abidjan 52
Padova 52
New York 49
Berlin 45
Los Angeles 43
Seoul 41
Redmond 40
Helsinki 36
Tokyo 36
Amman 33
Milan 32
Redondo Beach 32
Frankfurt am Main 31
San Diego 31
Sofia 30
Medford 28
Shenyang 28
Bern 27
Jinan 26
Changsha 24
Saint Petersburg 24
Abeokuta 23
Buffalo 22
Munich 22
Falkenstein 21
Ha Long 21
Hebei 21
Falls Church 20
Turin 20
Brussels 19
Tianjin 19
Biên Hòa 18
Haiphong 18
Nanchang 18
Dallas 16
Florence 16
Nuremberg 16
Bremen 15
Dearborn 15
Jiaxing 15
Zhengzhou 15
Guangzhou 14
Norwalk 14
Bengaluru 13
Da Nang 13
Mülheim 13
Jakarta 12
Phoenix 12
Thái Nguyên 12
Toronto 12
Des Moines 11
London 11
São Paulo 11
Taizhou 11
Mountain View 10
Rome 10
Shanghai 10
Bắc Ninh 9
Chicago 9
Hangzhou 9
Tehran 9
Washington 9
Atlanta 8
Brooklyn 8
Harbin 8
Ningbo 8
Ninh Bình 8
Vũng Tàu 8
Hải Dương 7
Kunming 7
Lappeenranta 7
Mahé 7
Montreal 7
Olalla 7
Totale 6.744
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 627
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 254
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 241
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 224
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 210
NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE 204
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 202
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 193
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 190
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 187
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 183
Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl 168
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 166
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 165
P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors 164
C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines. 158
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 158
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 157
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 157
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor 153
Best practices in chronic myeloid leukemia monitoring and management 152
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia 150
Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606 147
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 147
HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia 146
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 146
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 144
Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. 141
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 138
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 137
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 137
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 136
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis 135
Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells 134
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 132
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 131
mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein 130
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 130
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 128
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia 128
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 128
Recent advances in the molecular biology of systemic mastocytosis: Implications for diagnosis, prognosis, and therapy 127
The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities 126
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 126
Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. 123
A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias 123
Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma 121
The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein 118
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 118
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications 118
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 116
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 116
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 113
RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia 113
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 113
Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies 109
Cyclin-dependent kinase 2 (Cdk2) activity at the G1 to S boundary has a role in the resistance of Chronic Myeloid Leukemia (CML) haematopoietic progenitors to the tyrosine kinase inhibitor STI571 (Imatinib) 109
Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene 109
P210 BCR-ABL tyrosine kinase prevents apoptotic cell death through multiple pathways converging at mitochondrial membranes 109
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 108
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 106
Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia 104
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 101
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 101
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 100
Present and future of molecular monitoring in chronic myeloid leukaemia. 98
Systemic mastocytosis: Molecular landscape and implications for treatment 96
Idetification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. 92
Targeting leukemic stem cells in chronic myeloid leukemia: Is it worth the effort? 91
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia 86
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 81
You have accessClinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters 79
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 72
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib 2
Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3 sigma case. 2
Totale 10.484
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.623
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.623
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021611 0 0 0 0 0 51 26 57 83 41 49 304
2021/20221.273 138 25 78 83 117 77 28 87 57 85 250 248
2022/20231.640 185 263 88 197 119 128 59 73 281 41 133 73
2023/2024449 20 79 27 63 37 100 22 29 14 21 16 21
2024/20251.685 47 273 152 118 201 71 137 79 34 216 83 274
2025/20262.321 400 722 303 282 516 98 0 0 0 0 0 0
Totale 10.484